La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Moberg Pharma Gestione

Gestione criteri di controllo 2/4

Moberg Pharma's Il CEO è Anna Ljung, nominato in May2019, e ha un mandato di 5.25 anni. la retribuzione annua totale è SEK 3.51M, composta da 56.6% di stipendio e 43.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.016% delle azioni della società, per un valore di SEK 248.92K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 1.8 anni.

Informazioni chiave

Anna Ljung

Amministratore delegato

SEK 3.5m

Compenso totale

Percentuale dello stipendio del CEO	56.6%
Mandato del CEO	5.3yrs
Proprietà del CEO	0.02%
Durata media del management	4.9yrs
Durata media del Consiglio di amministrazione	1.8yrs

Aggiornamenti recenti sulla gestione

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Anna Ljung rispetto agli utili di Moberg Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-SEK 23m
Mar 31 2024	n/a	n/a	-SEK 23m
Dec 31 2023	SEK 4m	SEK 2m	-SEK 21m
Sep 30 2023	n/a	n/a	-SEK 18m
Jun 30 2023	n/a	n/a	-SEK 16m
Mar 31 2023	n/a	n/a	-SEK 16m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 16m
Sep 30 2022	n/a	n/a	-SEK 17m
Jun 30 2022	n/a	n/a	-SEK 16m
Mar 31 2022	n/a	n/a	-SEK 16m
Dec 31 2021	SEK 2m	SEK 1m	-SEK 16m
Sep 30 2021	n/a	n/a	SEK 8m
Jun 30 2021	n/a	n/a	SEK 7m
Mar 31 2021	n/a	n/a	SEK 5m
Dec 31 2020	SEK 3m	SEK 2m	SEK 7m
Jun 30 2020	n/a	n/a	SEK 20m
Jun 30 2019	SEK 476k	SEK 151k	-SEK 8m

Compensazione vs Mercato: La retribuzione totale di Anna ($USD 340.35K ) è circa la media per le aziende di dimensioni simili nel mercato Swedish ($USD 469.67K ).

Compensazione vs guadagni: La retribuzione di Anna è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Anna Ljung (44 yo)

5.3yrs

Mandato

SEK 3,511,000

Compensazione

Ms. Anna Ljung, M.Sc. Econ., BA serves as Chairperson of Biosergen AB since June 14, 2024. She served as Chairman of The Board at OncoZenge AB (publ) until August 2023. She joined company since 2020.Ms. L...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Anna Ljung	Chief Executive Officer	5.3yrs	SEK 3.51m	0.016% SEK 82.8k
Marie Moberg	Co-Founder	18.5yrs	SEK 193.70k	Nessun dato
Mark Beveridge	Vice President of Finance	4.9yrs	Nessun dato	0.033% SEK 174.5k
Christina Erixon	Head of Pharmaceutical Development & Operations	less than a year	Nessun dato	Nessun dato
Gunilla Wengström	Senior Director of Sales & Marketing	5.7yrs	Nessun dato	Nessun dato
Anders Broijersen	Chief Medical Officer	1.8yrs	Nessun dato	0.000020% SEK 104.9
Robert Ehrl	Head of Supply	less than a year	Nessun dato	Nessun dato

4.9yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di MOB è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Howard Maibach	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jonas Ekblom	Director	less than a year	Nessun dato	Nessun dato
Hakan Wallin	Independent Director	1.3yrs	SEK 99.00k	Nessun dato
Nikolaj Sorensen	Independent Director	3.3yrs	SEK 170.00k	0.17% SEK 900.9k
Jan Faergemann	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Lennart Emtestam	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Johan Heilborn	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Bernt Lindelöf	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Kerstin Strinnholm	Independent Chairman of the Board	2.3yrs	SEK 360.00k	0.19% SEK 1.0m

1.8yrs

Durata media

60.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MOB non è considerato esperto (durata media del mandato 1.8 anni), il che suggerisce un nuovo consiglio.

Moberg Pharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma Announces Leadership Changes

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

New minor risk - Market cap size

Now 64% undervalued after recent price drop

Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail Fungus

Price target increased by 26% to kr29.00

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Now 22% undervalued

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure

New major risk - Share price stability

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Moberg Pharma Announces Leadership Changes

Moberg Pharma AB (publ) Appoints Nomination Committee

Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America

New major risk - Shareholder dilution

Moberg Pharma AB (publ) Announces National Approval for MOB-015 in Sweden

Moberg Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults

Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European Union

New major risk - Market cap size

Moberg Pharma AB (Publ) Recommends for Approval in EU

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board Members

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Less than half of directors are independent

Moberg Pharma AB (publ) Appoints Anders Bröijersén as Chief Medical Officer and a Member of the Management Team

Moberg Pharma AB (publ), Annual General Meeting, May 16, 2023

Moberg Pharma AB (publ) Approves Board Appointments

Peter Wolpert and Fredrik Granström Step-Down from the Board

Moberg Pharma AB (Publ) Begins Patient Enrollment in North American Phase 3 Study

Moberg Pharma AB Announces Peter Wolpert and Fredrik Granström are Not Available for Re-Election

The Medical Products Agency in Sweden Will Be Reference Member State for Moberg Pharma's European Registration Application

Moberg Pharma AB Announces the Results from the North American Phase 3-Study with MOB-015 (topical terbinafine) for the Treatment of Onychomycosis

Moberg Pharma AB's Paid Subscription Units to Be Delisted

New 90-day low: kr6.40

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

New 90-day low: kr9.05

Market pulls back on stock over the past week

Moberg Pharma AB (publ) to Report Q1, 2021 Results on May 11, 2021

Moberg Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 09, 2021

Moberg Pharma AB (Publ) Appoints Nomination Committee

Moberg Pharma AB (publ), Annual General Meeting, May 18, 2021

New 90-day low: kr11.30

New 90-day low: kr13.52

Caret Pharma LLC entered into an agreement to acquire the assets of Fiber Choice® from Moberg Pharma AB (publ) (OM:MOB) for $6.7 million.

Moberg Pharma AB (publ)(OM:MOB) dropped from S&P Global BMI Index

New 90-day low - kr14.01

Earnings released

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media